Wells J A, Cunningham B C, Fuh G, Lowman H B, Bass S H, Mulkerrin M G, Ultsch M, deVos A M
Department of Protein Engineering, Genentech, Inc., South San Francisco, California 94080.
Recent Prog Horm Res. 1993;48:253-75.
High-resolution mutational and structural analyses of purified components have revealed a great deal about the molecular basis for growth hormone action. The structural and functional aspects of the interactions between hGH and its receptors have been largely elaborated. From these studies it has been possible to engineer homologues of hGH to bind to the hGH receptor and act as potential antagonists. Receptor-selective and high-affinity analogs have also been constructed based on a combination of alanine scanning and monovalent phage display. From this molecular work much has been revealed about the biology of hGH (Fig.9). Our data suggest that hGH is stored in the pituitary as a (Zn2+,hGH)2 complex. On release from somatotropic vesicles it dissociates into a monomeric form and reveals its primary receptor binding site (site 1). Free hGH can bind to the hGHbp in serum to form monomeric or dimeric complexes that slow the clearance of hGH (Moore et al., 1989). However, because the affinity for the full-length receptor is greater, hGH can bind to it preferentially. Furthermore, the constitutive levels of the hGHbp (approximately 0.5 to 1 nM) (Baumann et al., 1986; Herrington et al., 1986) are considerably below the levels of hGH after pulsatile release (approximately 2 to 5 nM) (Thompson et al., 1972). Our data indicate that hGH binds to the hGH receptor on cell membranes through site 1 and subsequently forms dimers through site 2. We believe a similar process may occur for hGH to activate the hPRL receptor, except that Zn2+ is required for site 1 association. Such receptor dimers are then activated and capable of interacting with other cellular components that may mediate the hGH "signal." Recently, based upon this proposed mechanism, we produced potent antagonists to the hGH receptor (Fuh et al., 1992) and hPRL receptor (G. Fuh, P. Colosi, W. Wood, and J. Wells, unpublished results). These antagonists bind tightly to site 1 but are blocked in their ability to bind site 2 and dimerize the receptor. We believe these methods and discoveries will be relevant to the study of signaling by other hematopoietic hormones and receptors as well as other hormones and receptors.
对纯化组分进行的高分辨率突变和结构分析揭示了许多关于生长激素作用分子基础的信息。hGH与其受体之间相互作用的结构和功能方面已得到很大程度的阐述。通过这些研究,已能够设计hGH的同源物,使其与hGH受体结合并充当潜在的拮抗剂。基于丙氨酸扫描和单价噬菌体展示相结合,还构建了受体选择性和高亲和力的类似物。从这项分子研究中,已揭示了许多关于hGH生物学的信息(图9)。我们的数据表明,hGH在垂体中以(Zn2+,hGH)2复合物的形式储存。从促生长小泡释放后,它解离为单体形式并暴露出其主要受体结合位点(位点1)。游离的hGH可与血清中的hGHbp结合形成单体或二聚体复合物,从而减缓hGH的清除(Moore等人,1989年)。然而,由于对全长受体的亲和力更大,hGH可优先与其结合。此外,hGHbp的组成水平(约0.5至1 nM)(Baumann等人,1986年;Herrington等人,1986年)远低于脉冲释放后hGH的水平(约2至5 nM)(Thompson等人,1972年)。我们的数据表明,hGH通过位点1与细胞膜上的hGH受体结合,随后通过位点2形成二聚体。我们认为,hGH激活hPRL受体可能发生类似过程,只是位点1的结合需要Zn2+。然后这些受体二聚体被激活,并能够与可能介导hGH“信号”的其他细胞成分相互作用。最近,基于这一提出的机制,我们制备了hGH受体的强效拮抗剂(Fuh等人,1992年)和hPRL受体的强效拮抗剂(G. Fuh、P. Colosi、W. Wood和J. Wells,未发表结果)。这些拮抗剂紧密结合在位点1,但在结合位点2和使受体二聚化的能力方面受到阻碍。我们相信这些方法和发现将与其他造血激素和受体以及其他激素和受体的信号传导研究相关。